Background
==========

Cardiovascular disease (CVD) is the leading cause of death among kidney transplant recipients (KTR) \[[@b1-anntransplant-24-100],[@b2-anntransplant-24-100]\]; therefore, a pre-transplant evaluation for prevalent CVD is commonly performed \[[@b3-anntransplant-24-100]\]. However, kidney transplant (KT) candidates are often asymptomatic despite constituting a population with a significant CVD burden \[[@b4-anntransplant-24-100]\]. More involved cardiac evaluation such as stress testing and invasive coronary angiography is expensive or may lead to further kidney damage \[[@b5-anntransplant-24-100]\]. Two-dimensional transthoracic echocardiography (TTE) provides non-invasive and accurate evaluation of cardiac function, especially for detecting left ventricular hypertrophy (LVH), a function of left-ventricular mass index (LVMI), and a significant independent risk factor for major adverse cardiovascular events (MACE) \[[@b6-anntransplant-24-100]\]. TTE is a popular pre-transplant assessment tool for screening purposes. However, it remains unclear whether information obtained from pre-operative echocardiography apart from LVH is significantly correlated with post-kidney transplant cardiac outcomes. There is mixed evidence for positive and negative cardiac remodeling post-transplant, as risk factors for volume and pressure overload compound after transplantation \[[@b6-anntransplant-24-100],[@b7-anntransplant-24-100]\]. TTE provides several measurements beyond LVMI, which although less often considered in TTE-based cardiac risk assessment may still predict MACE.

TTE provides data on relative wall thickness (RWT), which along with LVMI can be used to classify different left ventricular geometrical patterns \[[@b8-anntransplant-24-100]\]. For example, normal RWT and increased LVMI characterize a geometry known as eccentric hypertrophy. In studies of the general population, abnormal LV geometries relate adversely to prognosis, including carrying a higher incidence of MACE \[[@b9-anntransplant-24-100]--[@b12-anntransplant-24-100]\]. However, such data are scarce in KTR, particularly with respect to which pre-transplant LV geometries represent an increased risk for post-transplant MACE. As an inexpensive and widely performed pre-transplant screening procedure, any additional information that TTE provides might assist in customizing future pre- and post-transplant screening algorithms.

Material and Methods
====================

Study sample and follow-up
--------------------------

St. Michael's Hospital (SMH) is an urban university-affiliated tertiary-care medical-surgical center that actively follows over 1700 prevalent KTR and performs approximately 130 adult single-organ kidney transplants annually. Post-transplant clinic visits typically occur weekly to month 1, biweekly to month 3, monthly to month 6, quarterly to month 12, and twice annually or annually thereafter. At each clinic visit, trained personnel record anthropometry and resting blood pressure (BP). Ethnicity is recorded based on self-report. Laboratory testing is performed as close to each clinic visit as possible, with additional testing performed between visits according to a separate, more frequent schedule. The eGFR is calculated by the Modification of Diet in Renal Disease-7 equation \[[@b13-anntransplant-24-100]\]. As part of a standard protocol of evaluating KT candidates, a resting TTE and some form of cardiac stress testing is performed prior to transplantation. KT candidates who are found to demonstrate abnormalities by TTE or other tests are then referred to a cardiologist, after which these candidates may proceed to coronary angiography or other testing to help inform the decision about proceeding to kidney transplantation.

For this study, all KTR followed at SMH who underwent TTE within one year pre-transplant and were transplanted between October 1, 2006 and December 1, 2015 were first identified from the clinical electronic database. We then conducted an analysis of this population as of May 31, 2016 to ensure that all these patients had a minimum of 6 months potential post-transplant follow-up. No other exclusion criteria were applied for the study. The primary aim of this retrospective cohort study was to assess associations between parameters of pre-transplant LV geometry and post-transplant MACE. The secondary aim was to specifically assess the impact of an increased RWT or LVH on post-transplant MACE. Institutional research ethics board approval (REB10--204) was obtained for the study.

Patient assessment and data collection
--------------------------------------

MACE are routinely captured by transcriptions from local and citywide hospital databases as part of routine care, and supplemented by patient and family physician interviews where necessary. MACE was defined as the composite incidence of coronary revascularization, myocardial infarction, stroke, and cardiac death. Post-transplant MACE events were reviewed by at least 2 investigators.

TTE parameters were obtained from the transcribed reports of regional institutions that used standard M mode and two-dimensional images. For each TTE examination, left atrial diameter, diastolic septal wall thickness (SWTd), diastolic LV posterior wall thickness (LVPWTd), LV end-diastolic dimension (LVIDd), LV end-systolic dimension (LVIDs), end-systolic volume (ESV), and end-diastolic volume (EDV) were determined according to American Society of Echocardiography recommendations \[[@b14-anntransplant-24-100]\]. LVMI, RWT, and LV ejection fraction (LVEF) were calculated according to the same recommendations.

Patients were classified as having LVH if they had an LVMI greater than 100 g/m^2^ in women and greater than 131 g/m^2^ in men \[[@b15-anntransplant-24-100]\]. RWT, calculated using the formula 2\*LVPWTd/LVIDd, was considered increased when greater than 0.45 \[[@b16-anntransplant-24-100]\]. These divisions of LVMI and RWT were used to create 4 classifications of LV geometry: normal (no LVH and normal RWT), concentric remodeling (no LVH and increased RWT), eccentric hypertrophy (LVH and normal RWT), and concentric hypertrophy (LVH and increased RWT). The interaction between these dichotomized parameters was also evaluated.

Since this study was a retrospective review of clinic data pertaining to a prevalent KTR population, individual informed consent was not obtained. The study was performed in accordance with the 2000 Declaration of Helsinki and the 2008 Declaration of Istanbul.

Statistical analysis
--------------------

All analyses were conducted with R, version 3.4.0 (the R Foundation for Statistical Computing). All data are reported as mean ±SD, unless otherwise stated. Two-tailed p values below 0.05 were taken to imply statistical significance. All missing values were handled by exclusion from relevant analysis without imputation. Comparisons were made using the *t* test, Fisher exact test, chi-square test, competing risks analysis, or Cox proportional hazards analysis, as appropriate. Gray's modified chi-square statistic was used to test for differences between groups in competing risks analysis. Normality and skewness were assessed visually or with skewness tests for all subgroups, supplemented with the Shapiro-Wilk normality test for small-n subgroups. The proportionality of hazards assumption was tested with Schoenfeld residuals-based methods in R \[[@b17-anntransplant-24-100]\]. Selected covariates for multiple Cox regression models were based on biological plausibility, using variables determined at or prior to transplant, since risk was measured from transplantation \[[@b18-anntransplant-24-100]\].

Results
=======

Pre-transplant patient characteristics across LV geometries
-----------------------------------------------------------

A total of 1063 patients with pre-transplant TTE were identified on initial screening, corresponding to 86.8% of all patients transplanted during the study period. Of these, 469 (44%) patients were classified as normal, 340 (32%) as concentric remodeling (CR), 147 (14%) as concentric hypertrophy (CH), and 107 (10%) as eccentric hypertrophy (EH). Baseline transplant characteristics are shown and compared in [Table 1](#t1-anntransplant-24-100){ref-type="table"}. Recipients of a live donor transplant were overrepresented in the normal LV geometry group, and less represented among those with CH (42.9% normal *vs.* 24.5% CH, p\<0.001). Males were less likely to have LVH. With respect to other demographic parameters, no significant differences arose between groups. There was no statistically significant difference in pre-transplant MACE in the various hypertrophied groups. However, hypertension and diabetes as the primary cause of ESKD were each associated with abnormal LV geometry, particularly CH.

Early post-transplant patient characteristics and long-term graft outcomes
--------------------------------------------------------------------------

[Table 2](#t2-anntransplant-24-100){ref-type="table"} outlines patient characteristics at 3 months post-transplant. Those with CH tended to have a lower BMI (24.7±5.0 in CH *vs.* 26.44±5.2 in normal, p=0.006). Beta-blockers and angiotensin-II blockers were prescribed more in patients with CH. There were no significant differences in renal function or microalbuminuria, with GFR estimated by the Modification of Diet in Renal Disease formula. There was no difference in early graft function among the various groups. However, the cumulative incidence of graft failure was significantly higher with all abnormal LV geometries versus normal geometry (ranging from 19.7 to 22.4% for abnormal geometry *vs.* 12.1% for normal geometry, p=0.004).

MACE incidence post-transplant
------------------------------

[Figure 1](#f1-anntransplant-24-100){ref-type="fig"} depicts the differences in post-transplant MACE incidence expressed as the number of events per 100 patient-years. A higher MACE incidence was associated with the presence of any abnormal LV geometry. Differences between CR, CH, or EH and normal all reached statistical significance (p\<0.05).

MACE survival differences tested by the modified chi-square method are illustrated through cumulative incidence curves as shown in [Figure 2](#f2-anntransplant-24-100){ref-type="fig"} in which individual incidence curves for each geometry are shown. In competing risks analysis with non-cardiac death, MACE incidence for any non-normal LV geometry was significantly greater (15% *vs.* 10% at 1500 days post-transplant, p=0.003). Dichotomizing by RWT\>0.45, MACE incidence was significantly higher in those with increased RWT than with normal RWT (15% *vs.* 11% at 1500 days, p=0.046). Dichotomizing by LVH, those with LVH pre-transplant were at higher risk for both MACE and competing all-cause mortality (14% *vs.* 10% at 1500 days, p=0.030 for MACE, 3% *vs.* 5% at 1500 days, p=0.008 for all-cause mortality).

[Table 3](#t3-anntransplant-24-100){ref-type="table"} provides univariate Cox regression results for all measured echocardiogram parameters to MACE incidence. Both increased RWT and LVH dichotomization associated adversely with MACE-free survival (RWT: 1.416 (95% confidence interval 1.01--1.99) p=0.044; LVH: 1.521 (95% confidence interval 1.06--2.18) p=0.026). When RWT and LVMI were considered as continuous parameters, both continued to associate significantly with MACE (RWT: 8.72 (1.82--41.9) p=0.014; LVH: 1.01 (1.00--1.01) p\<0.001). Other echocardiographic parameters correlating strongly with increased MACE risk were left atrial diameter, right ventricular systolic pressure, LVPWTd, and SWTd (all p\<0.01).

Multiple regression for MACE incidence
--------------------------------------

Multivariate regression analyses associating RWT and LVH/LVMI with MACE incidence are shown in [Table 4](#t4-anntransplant-24-100){ref-type="table"}. Both RWT and LVH were independent of typical risk pre-transplant predictors of post-transplant CVD. Male sex, pre-transplant MACE, live donation, and smoking status were included in the model. Both LVH and LVMI associated significantly with MACE incidence (HR 1.58 (1.07--2.35) and 1.01 (1.00--1.01), respectively, both p\<0.05). RWT was significantly associated as a continuous, and dichotomized, parameter (continuous: HR 6.72 (1.27--35.7) p=0.025; dichotomous: HR 1.44 (1.02--2.01) p=0.041). When considering geometric classifications, any non-normal cardiac geometry was also independently associated with MACE (HR 1.60 (1.09--2.37), p=0.018). LVMI and RWT significantly interacted (p=0.008).

Discussion
==========

In this retrospective cohort study of a large, multi-ethnic KTR population, we suggest a possible predictive value to common pre-transplant echocardiographic parameters in the incidence of post-transplant MACE. The continuous variables LVMI and RWT and the categorical variable LVH were associated with post-transplant MACE, but these associations are unsurprisingly not fully independent of prior MACE, and may be mediated through causal mechanisms involving diabetes and systolic blood pressure. Nonetheless, identifying these pre-transplant echocardiographic abnormalities may assist in better focusing efforts on controlling these other long-term cardiovascular risk factors in KT candidates both before and after transplantation. RWT independently predicts cardiovascular events in patients with both hypertension and diabetes \[[@b19-anntransplant-24-100]\], and after myocardial infarction \[[@b20-anntransplant-24-100]\]. Specific classes of antihypertensive agents may affect RWT and LVMI selectively \[[@b21-anntransplant-24-100]\]. These associations and interventions have not been evaluated in ESKD patients or in KT candidates. The present study highlights that post-transplant cardiac prognosis with TTE can be further informed by LV geometry beyond LV hypertrophy alone. Increased RWT in isolation (concentric remodeling) can pose an equivalent hazard as concentric or eccentric hypertrophy, for example, and neither concentric nor eccentric hypertrophy geometries are associated with a greater hazard than the other. Absence of LVH does not imply absence of cardiovascular risk.

This study also provides evidence for the validity of the risk classification criteria typically used in the CKD population when assessing the importance of an increased RWT or LVMI. Transplant candidates with RWT over 0.45 or LVMI of 100--130 (depending on sex) may be at additively heightened risk for post-transplant MACE. Hence, the cutoffs for risk classification used in CKD and the general population appear to apply reasonably to pre-transplant candidates, in whom echocardiographic data are routinely obtained. Increased RWT and LVMI may situate along the causal pathway of other prognosticators of post-transplant cardiac health, such as pre-transplant MACE, diabetes, and uncontrolled hypertension. Although an association between echocardiography and MACE risk is well-documented in the general and dialysis/non-dialysis CKD populations \[[@b9-anntransplant-24-100],[@b10-anntransplant-24-100],[@b22-anntransplant-24-100]\], evidence is scarce in the CKD-KT candidate population \[[@b23-anntransplant-24-100]\]. To our knowledge, only one study regarding pre-transplant TTE and post-transplant MACE has been conducted, with a focus on wall motion abnormality in dobutamine stress echocardiography rather than resting LV geometry \[[@b24-anntransplant-24-100]\].

Concerns regarding kidney transplant candidate survival and allograft success drive extensive screening for cardiovascular disease prior to transplant. Such screening must be employed judiciously however, since pre-transplant tests and procedures are labor-intensive and expensive \[[@b23-anntransplant-24-100]\]. Echocardiography has previously been shown prospectively to exclude more invasive testing such as coronary angiography \[[@b21-anntransplant-24-100],[@b22-anntransplant-24-100]\]. In other studies \[[@b24-anntransplant-24-100]--[@b27-anntransplant-24-100]\], TTE and TTE-based multi-factor predictive models achieve high sensitivity and specificity for post-transplant MACE incidence, and in special subpopulations such as insulin-dependent diabetic KT candidates \[[@b28-anntransplant-24-100]\]. Many KT candidates have TTE performed as part of their dialysis initiation screening without screening for coronary artery disease *per se*. Increasing the interpretability and quantity of information that can be derived from TTE will further improve the ability of TTE and similar non-invasive echocardiography to potentially preclude other tests, if such tests are not specifically indicated. TTE provides more information than just the detection of LVH and the presence of regional wall motion abnormalities, whose finding usually dictates further cardiac investigation. Prospective clinical trials of intensive pre-transplant screening are currently lacking; recruitment to future trials of CVD prevention in KT candidates and KT recipients may be better informed by the enrichment with subjects who demonstrate select abnormalities on screening echocardiography.

This retrospective cohort study is inherently constrained by non-centralized echocardiographic evaluations, although its pragmatic applicability to other transplant institutions is also enhanced by the large sample size, making any center-based effect unlikely. Interventions were not controlled between groups, although medication profiles tended to not differ significantly between groups. Furthermore, the time between TTE and transplant varied, reaching up to 1 year prior to transplant. Depending on proximity to last dialysis, echocardiographic measurements of cardiac chamber sizes (although not necessarily wall thickness) may have been influenced by patient blood volume \[[@b21-anntransplant-24-100]\]. As this was primarily an echocardiographic investigation, we did not have information on electrocardiographic abnormalities and had limited information about pre-transplant or post-transplant biochemical and pharmacological parameters. We studied only patients who were successfully transplanted, not those who were delisted or died while waiting for a transplant. Lastly, the correlations in this study do not imply causation, but simply identify a subset of KT candidates for further study. The main strength of the study, however, is the size and multi-ethnicity of its cohort with minimal exclusions to better represent the largest possible proportion of KT candidates receiving a transplant, as well as a long post-transplant follow-up of these candidates for the occurrence of MACE.

Conclusions
===========

TTE in KT candidates beyond LVH alone can better inform the risk of post-transplant MACE. Additional information on LV geometry, including RWT, LVMI, and LVH patterns, improves the assessment of that risk and may serve to more effectively address other CVD risk factors in the pre-transplant ESKD population. Considering abnormal LV geometrical parameters, including concentric remodeling or eccentric hypertrophy, as being at risk for MACE besides those with LVH, may also help identify potential KT candidates to enrich recruitment to prospective clinical trials of CVD prevention after kidney transplantation.
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![Incidence rate of MACE within pre-transplant LV geometry groups. Units expressed in events per 100 patient-years at risk. Incidence rate is shown for each group over each bar. Significance was assessed via *t* test with comparison to normal geometry. Incidence rate differences assessed using an expanded definition of MACE (any cardiac event), including new-onset diagnosed coronary artery disease, congestive heart failure, or atrial fibrillation within tracked events.](anntransplant-24-100-g001){#f1-anntransplant-24-100}

![Cumulative incidence of MACE across strata of LV geometrical parameters. All-cause mortality included as a competing risk for all tests, and cumulative all-cause mortality incidence is plotted in the LVH and RWT panels. P values indicate the significance of difference between groups for MACE incidence only. Death incidence curves for panel 3 were excluded to improve clarity.](anntransplant-24-100-g002){#f2-anntransplant-24-100}

###### 

Baseline patient or transplant characteristics across LV geometry types.

  Characteristic               Normal (n=469)   Con. rem. (n=340)   Con. hyp. (n=147)   Ecc. hyp. (n=107)   *P*
  ---------------------------- ---------------- ------------------- ------------------- ------------------- ---------
  Demography data                                                                                           
   Avg. f/u from tx. (years)   3.65±2.44        3.49±2.36           3.98±2.58           3.69±2.6            0.247
   Age at tx. (years)          52.5±13.0        52.9±12.9           51.8±13.4           51.3±14.            0.656
   Male (N, % male)            291, 62.1%       235, 69.1%          71, 48.3%           48, 44.9%           \<0.001
   Ethnicity (N, % white)      104, 22.2%       69, 20.29%          25, 17.01%          18, 16.8%           0.423
   Smoking (N, % smoking)      173, 36.8%       126, 37.0%          53, 36.0%           37, 34.5%           0.968
   Pre-tx MACE                 54, 11.5%        49, 14.4%           23, 15.7%           18, 16.8%           0.333
  ESKD cause (N, %)                                                                                         
   Hypertension                44, 9.4%         43, 12.7%           30, 20.4%           12, 11.2%           0.005
   Polycystic KD               63, 13.4%        29, 8.5%            12, 8.2%            9, 8.4%             0.073
   Diabetes Mellitus           79, 16.8%        78, 22.9%           35, 23.8%           14, 13.1%           0.026
   Glomerulonephritis          163, 34.8%       100, 29.4%          42, 28.6%           33, 30.8%           0.316
   Unknown/other               141, 30.1%       104, 30.6%          41, 27.9%           43, 40.2%           0.164
  Allograft Data                                                                                            
   Hemodialysis                206, 43.9%       165, 48.5%          77, 52.4%           59, 55.1%           0.039
   Not dialysed                68, 14.5%        34, 10.0%           6, 4.1%             5, 4.7%             \<0.001
   Avg. dialysis vintage       4.50±4.0         4.64±3.7            6.70±4.8            5.05±3.8            \<0.001
   Second + transplant         24, 5.1%         19, 5.6%            12, 8.2%            5, 4.7%             0.534
   Live donor (N, % live)      201, 42.9%       108, 31.8%          36, 24.5%           33, 30.8%           \<0.001

MACE defined as vascular surgery, MI, stroke, or cardiac-related death. Comparisons made with 2x4 contingency table analysis for dichotomous factors, or ANOVA for continuous variables.

###### 

Three-month and long-term post-transplant patient characteristics across LV geometries.

  Characteristic                   Normal (n=469)   Con. rem. (n=340)   Con. hyp. (n=147)   Ecc. hyp. (n=107)   *P*
  -------------------------------- ---------------- ------------------- ------------------- ------------------- ---------
  Physical measurements                                                                                         
   SBP (mmHg)                      129.±41.3        130.1±47.0          128.5±44.0          131.2±48.0          0.958
   DBP (mmHg)                      79.7±25.6        79.1±29.2           77.3±26.7           78.4±28.8           0.834
   Height (cm)                     168.±56.4        170.±64.0           166.2±58.0          165.7±60.0          0.929
   Weight (kg)                     75.6±28.1        76.9±31.7           69.0±26.2           72.6±29.6           0.062
   BMI (kg/m^2^)                   26.44±5.2        26.5±5.00           24.72±5.0           26.3±5.55           0.006
  Laboratory measurements                                                                                       
   Fasting glucose (mmol/L)        6.09±2.87        6.88±3.67           6.27±3.06           6.56±3.22           0.012
   Random glucose (mmol/L)         6.58±3.50        7.28±4.18           6.63±3.15           7.10±3.91           0.073
   HbA1c (% glycated Hb)           0.06±0.02        0.06±0.02           0.06±0.02           0.06±0.02           1.000
   Total cholesterol (mmol/L)      4.44±1.81        4.50±2.07           4.55±1.78           4.34±1.76           0.840
   HDL-cholesterol (mmol/L)        1.32±0.59        1.34±0.66           1.34±0.61           1.31±0.62           0.960
   LDL-cholesterol (mmol/L)        2.36±1.24        2.42±1.41           2.49±1.24           2.23±1.14           0.502
   Triglycerides (mmol/L)          1.82±1.50        1.70±1.06           1.73±1.10           1.78±0.98           0.661
   C-reactive protein (mg/L)       5.20±10.7        7.77±21.1           5.42±10.3           4.87±8.43           0.098
  Renal function/outcomes                                                                                       
   Serum creatinine (micromol/L)   128.±73.1        134.±80.8           120.3±58.0          121.1±67.0          0.245
   Estimated GFR (mdrd)            54.6±24.0        54.0±26.6           53.7±23.5           55.1±25.9           0.968
   MACR (mcg/L)-to-(mmol/L)        11.5±33.7        17.4±59.4           8.06±12.7           13.9±47.9           0.157
   24 h urine prot. (mmol/L)       0.52±0.42        0.74±0.81           0.61±0.55           0.95±0.80           0.002
   Graft failure incidence         57, 12.1%        69, 20.3%           29, 19.7%           24, 22.4%           0.004
   MACE (per 100p-y)               43, 2.66         47, 4.31            26, 4.86            18, 5.34            \<0.001
  Medications (N, %)                                                                                            
   Statin                          224, 47.8%       174, 51.2%          67, 45.6%           50, 46.7%           0.634
   ACE inhibitor                   54, 11.5%        26, 7.7%            11, 7.5%            7, 6.5%             0.145
   Beta-blocker                    163, 34.8%       142, 41.8%          74, 50.3%           48, 44.9%           0.004
   Angiotensin II blocker          57, 12.2%        54, 15.9%           31, 21.1%           19, 17.8%           0.028

MACE defined as post-transplant MI, stroke, angioplasty/CABG, other vascular surgery, or cardiac-related death. Comparisons made with 2×4 chi-square analysis for dichotomous factors, or ANOVA for continuous factors. Graft failure and MACE are long-term outcomes.

###### 

Univariate Cox proportional hazards regressions for MACE incidence.

  Variable                        HR (95% CI)          P
  ------------------------------- -------------------- ---------
  LV geometry parameters                               
   "Increased" RWT (\>0.45)       1.416 (1.01--1.99)   0.044
   LVH (LVMI \>100 or \>131)      1.521 (1.06--2.18)   0.026
  Other echocardiogram data                            
   RV syst. pressure (mmHg)       1.024 (1.01--1.04)   0.007
   Left atrial diameter (cm)      1.564 (1.21--2.03)   \<0.001
   LVIDd (cm)                     1.086 (0.82--1.42)   0.550
   LVIDs (cm)                     1.097 (0.84--1.43)   0.498
   LVPWTd (cm)                    3.996 (1.68--9.50)   0.002
   SWTd (cm)                      5.412 (2.63--11.0)   \<0.001
   End systolic volume (cm^3^)    1.002 (1.00--1.01)   0.539
   End diastolic volume (cm^3^)   1.002 (1.00--1.01)   0.466
   LV ejection fraction (%)       0.894 (0.26--3.12)   0.861
   Relative wall thickness        8.715 (1.82--41.9)   0.007
   LV mass index (g/m^2^)         1.008 (1.00--1.01)   \<0.001

RWT=2^\*^LVPWd/LVIDd, unitless ratio of cm/cm. LVH diagnosis based on an LVMI\>100 g/m^2^ in women and \>131 g/m^2^ in men.

###### 

Multivariate Cox proportional hazards regressions for MACE incidence, comparing RWT, LVMI, and LVH type to common predictors of post-transplant MACE.

  Variable            HR (95% CI)         P       Variable            HR (95% CI)         P
  ------------------- ------------------- ------- ------------------- ------------------- -------
  **Non-normal LV**   1.60 (1.09--2.37)   0.018   **RWT (cm/cm)**     6.72 (1.27--35.7)   0.025
  Male                1.40 (0.91--1.13)   0.122   Male                1.37 (0.89--2.09)   0.147
  Live donor          0.74 (0.50--1.11)   0.144   Live donor          0.75 (0.50--1.12)   0.154
  Smoking             1.57 (0.07--2.29)   0.020   Smoking             1.57 (1.08--2.30)   0.019
  Prior MACE          2.29 (1.49--3.52)   0.001   Prior MACE          2.29 (1.49--3.51)   0.002
  **LVH**             1.58 (1.07--2.35)   0.022   **LVMI (g/m^2^)**   1.01 (1.00--1.01)   0.015
  Male                1.47 (0.96--2.27)   0.079   Male                1.27 (0.82--1.95)   0.279
  Live donor          0.74 (0.50--1.11)   0.144   Live donor          0.74 (0.50--1.11)   0.150
  Smoking             1.50 (0.92--2.19)   0.039   Smoking             1.47 (1.01--2.16)   0.047
  Prior MACE          2.31 (1.50--3.55)   0.001   Prior MACE          2.29 (1.49--3.53)   0.002

All variables listed except "LVMI" and "RWT" are dichotomous (0=no, 1=yes). Normal LV refers to RWT\<0.45 and no LVH. RWT=2^\*^LVPWd/LVIDd.
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